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A patient presented with fever, night sweats, generalized lymphadenopathy, cold agglutinin
hemolytic anemia, and thrombocytopenia. Lymph node biopsy revealed a lymphoplasmacytic
infiltrate sparing the cortical sinuses but associated with arborizing blood vessels. Epstein-Barr
virus (EBV) DNA was demonstrated in tissue from an involved lymph node. These data suggest
an association of EBV with a lymphoproliferative process that resembles angioimmunoblastic
lymphadenopathy with dysproteinemia.
INTRODUCTION
Since its discovery in cultured lymphoblasts from a patient with Burkitt's lymphoma
[1], Epstein-Barr virus (EBV) has been linked to a number of lymphoproliferative
syndromes [2,3]. EBV shows a tropism for nasopharyngeal epithelial cells and B
lymphocytes, the latter becoming immortalized when infected. Infectious mononucleo-
sis, the most common clinical manifestation ofacute EBV infection, is associated with
polyclonal B-cell proliferation, which is evidently controlled by cytotoxic T cells,
natural killer cells, and neutralizing antibodies. In immunocompromised hosts, how-
ever (e.g., patients with the X-linked lymphoproliferative syndrome, organ transplant
recipients, and patients with human immunodeficiency virus infections), EBV infec-
tion may progress to fatal lymphoproliferation or lymphoma [2,3].
In the early 1970s, several groups described a lymphoproliferative syndrome in
elderly patients, consistingofgeneralized lymphadenopathy, fever, hepatosplenomega-
ly, skin rash, malaise, Coombs-positive hemolytic anemia and other hematologic
syndromes, and polyclonal hypergammaglobulinemia; this syndrome is usually re-
ferred to as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) or
immunoblastic lymphadenopathy [4-6]. Several groups have subsequently described
patients whose clinical presentation resembles AILD but who lack some of its
histological features; this syndrome is usually termed autoimmune-associated lymph-
adenopathy [7-9]. The etiology of AILD and related syndromes remains unclear
[4-6,10,11].
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We report a patient who presented with clinical and histologic features suggestive of
AILD (though lacking the classic histologic features), who had EBV genome detected
by Southern blot analysis in a pathologically involved lymph node.
CASE REPORT
The patient was a 61-year-old white man who presented in October 1985 to the West
Haven Veterans Administration Medical Center with a four-week history of lethargy,
malaise, chills, fever, night sweats, and abdominal pain. On physical examination, he
had a temperature of 1020F, generalized lymphadenopathy, and a palpable spleen.
Laboratory evaluation included a hemoglobin of 5.9 g/dL, hematocrit of 14.2 percent,
platelet count of 96,000/mm3, and a white cell count of 12,500/mm3 with 1 percent
band forms, 72 percent polymorphonuclear leukocytes, 10 percent lymphocytes, 15
percent monocytes, 2 percent atypical lymphocytes, and a reticulocyte count of <0.1
percent. The peripheral blood smear was remarkable for plasmacytoid lymphocytes
and rouleaux formation. Total protein was 7.2 g/dL, albumin 3.6 g/dL. Serum protein
electrophoresis showed multiple faint bands extending from the beta through the
gamma regions. A strongly reacting, low-titerIgM cold agglutinin was present, which
reacted equally with adult and umbilical cord cells. Skin tests showed the patient to be
anergic to candida and mumps. Abdominal and chest CT scans confirmed the presence
of generalized lymphadenopathy and splenomegaly. Bone marrow aspirate and biopsy
showed hypercellularity, focal fibrosis, and increased numbers of large mononuclear
cells. A left supraclavicular lymph node biopsy revealed almost total effacement of the
normal architecture by a lymphoplasmacytic infiltrate composed of cells with a coarse
and blotchy chromatin pattern, rare mitoses, and a few eccentric nuclei; the infiltrate
stained strongly positive with methyl green pyronine. Immunohistochemical stains
showed staining with antibody to kappa and lambda light chains as well as to T-cell
markers. The patient was transfused and begun on prednisone, 100 mg per day, in an
attempt to control the anemia and thrombocytopenia. The patient's anemia, thrombo-
cytopenia, and fevers slowly resolved. After four weeks of therapy, the dose of
prednisone was tapered. He again developed fever, night sweats, and abdominal pain.
Eight weeks following his initial admission, the patient was readmitted for evalua-
tion of hematochezia; at this time, his prednisone was stopped. On the third hospital
day, he developed epistaxis and fever. His hemoglobin was 11.6g/dL, hematocrit
35.6 percent, platelet count 2,000/mm3 (down from 166,000 six days earlier), and
reticulocyte count 4 percent. Cold agglutinins were negative; direct Coomb's test was
positive for anti-C3. He was started on high-dose methylprednisolone in an attempt to
control his thrombocytopenia and on mezlocillin and gentamicin empirically. On this
regime, he developed a macular rash, which resolved when the antibiotics were
discontinued. Despite high doses of steroids, daily fevers, hemolysis, and thrombocyto-
penia persisted. A right axillary lymph node biopsy revealed complete effacement of
the node and infiltration of the perinodal fat by lymphoplasmacytic cells, similar to
that seen in the previous lymph node biopsy. There was minimal involvement of the
cortical sinuses. Proliferation of arborizing blood vessels was noted, but necrosis and
eosinophilic material were not present. Immunofluorescence staining of cells from the
node showed that 63 percent were Leu 4 positive, 16 percent Leu 3 positive, 41 percent
Leu 2 positive (T helper: T suppressor, 0.39:1), 36 percent B1 positive, 25 percent
positive for anti-lambda, and 25 percent positive for anti-kappa. In January of 1986,
the patient underwent splenectomy, exploratory laparotomy, abdominal lymph node
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biopsy, and liver biopsy. The spleen showed congestion and a polymorphic infiltrate.
The liver was normal. Routine cultures of lymph node tissue for bacteria, mycobacte-
ria, fungi, and viruses were negative. Over the next ten weeks, as the prednisone was
gradually discontinued, fever, hemolytic anemia, and thrombocytopenia resolved.
Except for lymphadenopathy, which has continued to wax and wane, he has remained
well throughout 22 months offollow-up.
METHODS
EBVSerology
Antibodies to EBV capsid (VCA), early (EA), and nuclear (EBNA) antigens were
detected by standard immunofluorescence techniques [12].
Immunofixation Electrophoresis
Immunofixation electrophoresis was performed as previously described [13] on
samples from the patient's initial admission. Samples included serum as well as cold
agglutinins, which were eluted from the patient's red cells with warm saline after
washing the cells with cold saline.
Detection ofEBVDNA
DNA was extracted from the patient's abdominal lymph node biopsy and probed,
essentially as previously described. Briefly, approximately two grams of the patient's
lymph node was sliced and shredded with a razor blade, suspended in phosphate
buffered saline without Ca2" or Mg2", and put through 15 strokes of a homogenizer.
The homogenate was digested first with pronase and sodium dodecyl sulfate and then
with RNAse, with a final precipitation in 95 percent ethanol [14]. Approximately
three micrograms ofthe resulting cellular DNA was then digested with the restriction
endonuclease BamHI, electrophoresed on a 0.5 percent agarose gel, and transferred to
nitrocellulose, using Southern's method [15]. EBV DNA sequences were detected by
probing with theEcoRI A DNA fragmentofthestandard EBV strain FF41 in plasmid
pACYC, labeled with [32P]dCTP by nick translation [14].
RESULTS
Immunofixation electrophoresis showed at least five distinct IgM bands, with both
IgM-lambda and IgM-kappa bands. Immunofixation electrophoresis of the cold
agglutinins also revealed IgM with both lambda and kappa light chains.
Viral serologies are presented in Table 1. The patient shows evidence of previous
EBV infection, as determined by the presence of titers to both VCA and EBNA and
the absence ofeither IgM antibody to VCA or a rising IgG VCA antibody titer.
DNA extracted from the patient's abdominal lymph node was positive for EBV
DNA by Southern blot analysis (see Fig. 1). The strongest hybridization was to the
BamHI W fragment, which is to be expected since it is a repeated element in the EBV
genome. The usual hybridization to the other BamHI fragments (C, F, and H) within
EcoRI A was also seen. (BamHI fragment Q is often not observed even though it is
within EcoRI A because it is so close in molecular weight to the repeated BamHI W
fragment; BamHI Y does not always resolve well, because it is near the limit of
resolution of a 0.5 percent agarose gel. BamHI H commonly varies in size between
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TABLE 1
Viral Titers
Abdominal
Admission Surgery
Antigen 10/85 12/85 1/86 3/86
EBV VCA
IgG 1:320 1:640 1:640 1:320
IgM <1:10 <1:10
EA restricted 1:20 1:40 1:40 1:20
EA diffuse 1:5 1:5 <1:5 1:5
EBNA 1:20 1:40 1:20 1:40
CMV 1:32 1:32 1:32
HIV Negative
Serologies to Epstein-Barr virus VCA, EA, and EBNA as well as to cytomegalovirus (CMV) were
measured with standard immunofluorescence techniques. HIV titer was measured by ELISA.
different isolates ofEBV, as itdoes here between thecontrol and thepatient's specimen
[16]).
DISCUSSION
The etiology of AILD and related syndromes is unknown. The development of this
family ofdisorders has variously been associated with allergens, toxins, and infectious
agents; however, whether one of these actually triggers the onset of the disease is
unknown. (For a recent review, see [17]). The histologic picture is suggestive of a
reactive process, composed predominantly of T lymphocytes. Recent studies suggest
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W - FIG. 1. Detection ofEBV DNA in the patient's lymph node. Approximately
three ,ug oftotal cellular DNA from the patient's lymph node (specimen) or 15 ,g
of control DNA (from a known EBV-positive lymphoblastoid cell line) were
digested with the restriction enzyme BamHI and probed with a nick-translated,
V - [32PJ-labeled plasmid containing the EcoRI A region from a standard laboratory
strain ofEBV. TheBamHI fragments resulting from thedigestion areshown at the
left ofthe figure; for further details, see text.
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that, when examined by probes for rearranged immunoglobulin and T-cell receptor
genes, clonal expansion of T and/or B cells may be seen [18-20]. Because of these
data, and the fact that up to 20 percent ofcases can progress to lymphoma, there has
been much speculation that this group of syndromes represents a pre-lymphomatous
state [17,18,21].
In our case, while there was the suggestion of oligoclonal bands on serum protein
electrophoresis and immunofixation electrophoresis, no evidence ofa prominent clonal
lymphoproliferation was present in lymph node tissue when examined by immunohis-
tochemical and immunofluorescence staining of lymph node cells. EBV genome was
demonstrated, however, despite the factthat thepatient did not haveserologic evidence
ofacute or reactivation infection.
Previous studies have demonstrated EBV DNA and EBNA in lymphoid tumors
from patients with organ transplants, AIDS, and other immunodeficiencies, in the
central nervous system, and African Burkitt's lymphoma, as well as in epithelial cells
from patients with nasopharyngeal carcinoma, and, recently, in T-cell lymphomas
from patients with severe, chronic EBV infections [1,2,3,14,22-28]. In contrast,
studies using Southern blotting have only rarely demonstrated the presence of EBV
DNA in a large number of other lymphoproliferative processes, even in the immuno-
suppressed [14]. These EBV-associated lesions are usually but not invariably accom-
panied by serologic evidence of EBV reactivation in the affected individual; in fact,
EBV serologic responses may be abnormal in immunocompromised patients, even in
the face ofa progressive EBV infection [29]. Thus, a role for EBV in the pathogenesis
of this patient's lymphoproliferative process cannot be excluded on the basis of
serologic data.
Bornkamm et al. described one case of immunoblastic lymphadenopathy in which
EBV DNA was demonstrated by reassociation kinetics [30]. Virelizier et al. described
a child with presumed AILD who had persistently elevated titers to EBV antigens in
serum and EBNA in affected lymph node cells [17,31]. We now report an additional
association of EBV DNA, as detected by Southern blot analysis, with an AILD-like
syndrome. Taken together, these reports suggest an association between EBV and a
small number of lymphoproliferative syndromes associated with autoimmunity, such
as AILD.
What role EBV or any other associated agent plays in the pathogenesis ofAILD or
AILD-like illness is, at present, unclear. The increased number ofsuppressor T cells in
the involved lymph node may have been a reaction to virally infected B cells. It is also
conceivable, however, that EBV may have infected the patient's T cells, as has been
described for some T-cell lymphomas in patients with severe, chronic EBV infections
[27,28].
Studies ofthe nature ofthe EBV infection associated with various lymphoprolifera-
tive disorders may further understanding of the pathogenesis of these diseases. In
addition, more sensitive genomic analysis ofbiopsied material, especially the useofthe
polymerase chain reaction, will probably add to the expanding spectrum of EBV-
associated disorders.
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